Dalbavancin Therapy for Infective Endocarditis | MicrobiomeTrials← Back to trialsNCT07699211
Dalbavancin Therapy for Infective Endocarditis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-12Est. Completion: 2028-09
Enrollment target: 184 participants Locations- Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Universitätsklinikum Regensburg, Regensburg, Bavaria, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Free and Hanseatic City of Hamburg, Germany
- Universitätsklinikum Köln, Cologne, North Rhine-Westphalia, Germany
- Klinikum St. Gerog gGmbh, Leipzig, Saxony, Germany
- Vivantes Auguste-Viktoria-Klinikum, Berlin, State of Berlin, Germany
- Deutsches Herzzentrum der Charité (DHZC), Berlin, State of Berlin, Germany
- Helios Klinikum Erfurt GmbH, Erfurt, Thuringia, Germany
- University Hospital Jena, Jena, Thuringia, Germany
Other microbiome trials you might be interested in
BacteremiaInfective Endocarditis
This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be preve…
Boston, United StatesEst. completion Sep 2027
Aortic Stenosis
Aortic stenosis (AS) affects approximately 5% of individuals \>65 years old, with \~3% of people \>75 years having moder…
Garran, AustraliaEst. completion Apr 1, 2031
Endocarditis
Endocarditis, Bacterial
The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of I…
London, United KingdomEst. completion Apr 24, 2029